FORM N-PX FILER INFORMATION

Form N-PX

Name of reporting person (For registered

UNITED STATES **SECURITIES AND EXCHANGE** COMMISSION

Washington, D.C. 20549

FORM N-PX ANNUAL REPORT OF PROXY VOTING RECORD

C
)
١
V
В
1
Α
Ρ
Р
R
О
٨
/A
١

OMB Number:

3235-0582

Estimated average burden hours per response: 20.8

N-PX: Filer Information	on							
Filer CIK:	0001388325							
Filer CCC:	ot*fjs4o							
Date of Report:	06/30/2025							
Are you a Registered Management Investment Company or an Institutional Manager?	Institutional Manager							
Filer Investment Company Type								
Is this a LIVE or TEST Filing?	LIVE							
Is this an electronic copy of an official filing submitted in paper format?								
Submission Contact Information								
Name	EDGAR Advantage Service Team							
Phone	800-688-1933							
E-mail Address	e-support@toppanmerrill.com							
Notification Information								
Notify via Filing Website only?								
Notification E-mail Address:	west@toppanmerrill.com							
	·							
N-PX: Series/Class (Contract) Information								
N-PX: Cover Page								
Name and address of reporting person:								

Novo Holdings A/S

Tuborg Havnevej 19
Hellerup
G7
DK-2900
45-3527-6592
Report for the year ended June 2025 30,
028-16231
Registered Management Investment Company. Fund Voting Report (Check here if the registered management investment company held one or more securities it was entitled to vote.) Fund Notice Report (Check here if the registered management investment company did not hold any securities it was entitled to vote.) Institutional Manager. Institutional Manager Voting Report (Check here if all proxy votes of this reporting manager are reported in this report.) Institutional Manager Notice Report (Check here if no proxy votes are reported in this report and complete the notice report filing explanation section below) Institutional Manager Combination Report (Check here if a portion of the proxy votes for this reporting manager are

Confidential Treatment Requested. (The Institutional Manager has omitted from this public Form N-PX one or more proxy vote(s) for which it is requesting confidential treatment from the U.S. Securities and Exchange Commission pursuant to the instructions of this form):	reported in this report and a portion are reported by other reporting person(s).)									
Do you wish to provide explanatory information pursuant to Special Instruction B.4?:	Yes X No									
Additional information:										
N-PX: Summary - Included Managers Number of Included Institutional Managers: 0 N-PX: Signature Block										
Reporting Person:	Novo Holdings A/S									
By (Signature):	Barbara Fiorini									
By (Printed Signature):	Barbara Fiorini									
By (Title):	General Counsel, Finance & Operations									
Date:	08/29/2025									

FORM N-PX PROXY VOTING RECORD

COLUMN 1	COLUMN 2	COLUMN 3	COLU MN 4	COLUMN 5	MN 5 COLUMN 6	COLUMN 7	COLUMN 8	COLUMN 9	COLUMN 10	COLUMN 11	COLUMN 12			COLUMN 13	COLUMN 14	COLUMN 15
NAME OF ISSUER	CUSIP	ISIN	FIGI	MEETING	VOTE DESCRIPTION	VOTE CATEGORY	DESCRIPTI	VOTE	SHARES	SHARES	DETAILS OF VOTE			MANAGER NUMBER	SERIES ID	OTHER IN
				DATE	DESCRIPTION	CATEGORY	ON OF OTHER CATEGORY	SOURCE	VOTED	ON LOAN	HOW VO TED	SHARES V OTED	FOR OR AGAINST MANAGE MENT	NUMBER		FO
4D Molecular Therapeutics, Inc.	35104E100	US35104E1001		06/17/2025	Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").	SECTION 14A SAY-ON-PAY VOTES			2000000	0	FOR	2000000	FOR			
4D Molecular Therapeutics, Inc.	35104E100	US35104E1001		06/17/2025	Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes.	SECTION 14A SAY-ON-PAY VOTES			2000000	0	1 YEAR	2000000	FOR			
AbCellera Biologics Inc.	00288U106	US00288U1060		06/12/2025	To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, or Say on Pay.	SECTION 14A SAY-ON-PAY VOTES			1126915	0	FOR	1126915	FOR			
Amicus Therapeutics, Inc.	03152W109	US03152W1099		06/05/2025	Approval, on an advisory basis, the Company's executive compensation.	SECTION 14A SAY-ON-PAY VOTES			2829626	0	FOR	2829626	FOR			
Biomarin Pharmaceutical Inc.	09061G101	US09061G1013		05/20/2025	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.	SECTION 14A SAY-ON-PAY VOTES			490000	0	FOR	490000	FOR			
Blueprint Medicines Corporation	09627Y109	US09627Y1091		06/18/2025	Approval of a non-binding advisory vote on the compensation paid to our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			264956	0	FOR	264956	FOR			
Crinetics Pharmaceuticals, Inc.	22663K107	US22663K1079		06/11/2025	To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.	SECTION 14A SAY-ON-PAY VOTES			1275000	0	FOR	1275000	FOR			
Celldex Therapeutics, Inc.	15117B202	US15117B2025		06/05/2025	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.	SECTION 14A SAY-ON-PAY VOTES			1200000	0	FOR	1200000	FOR			
Edgewise Therapeutics, Inc.	28036F105	US28036F1057		06/13/2025	Conduct an advisory vote on the compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			5350000	0	FOR	5350000	FOR			
Edgewise Therapeutics, Inc.	28036F105	US28036F1057		06/13/2025	Conduct an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			5350000	0	1 YEAR	5350000	FOR			
Insmed Incorporated	457669307	US4576693075		05/15/2025	An advisory vote on the 2024 compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			724666	0	FOR	724666	FOR			
Marqeta, Inc.	57142B104	US57142B1044		06/12/2025	To approve, on a non-binding advisory basis, the compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES			441558	0	FOR	441558	FOR			
Mirum Pharmaceuticals, Inc.	604749101	US6047491013		05/29/2025	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.	SECTION 14A SAY-ON-PAY VOTES			1500000	0	FOR	1500000	FOR			

Recursion Pharmaceuticals, Inc.	75629V104	US75629V1044	06/18/2025		SECTION 14A SAY-ON-PAY VOTES	966512	8 0	FOR	9665128	FOR		
Rocket Pharmaceuticals, Inc.	77313F106	US77313F1066	06/18/2025	Consider and act upon a non- binding, advisory vote on the compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES	110000	0	FOR	1100000	FOR		
Salesforce, Inc.	79466L302	US79466L3024	06/05/2025	Approval, on an advisory basis, of the fiscal 2025 compensation of our named executive officers.	SECTION 14A SAY-ON-PAY VOTES	330187	0	FOR	330187	FOR		
Vaxcyte, Inc.	92243G108	US92243G1085	06/12/2025	Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.	SECTION 14A SAY-ON-PAY VOTES	916160	0	FOR	916160	FOR		
Verve Therapeutics, Inc.	92539P101	US92539P1012	06/05/2025	Approval, on an advisory basis, of the compensation paid to our named executive officers.	SECTION 14A SAY-ON-PAY VOTES	317000	0	FOR	3170000	FOR		
Viridian Thereaputics, Inc.	92790C104	US92790C1045	06/20/2025	To approve, on an advisory basis, the compensation of the Company's named executive officers.	SECTION 14A SAY-ON-PAY VOTES	232764	0	FOR	2327640	FOR		